It is great to finally see the Pulse released. However, I don't feel there will be a re-rate short term. 30 units a day (say $3-4m revenue), does very little to shift the revenue dial. We'd need $50m to $100m in order to start being seen as a billion dollar market cap as has been alluded to. And while the hype, progress reports and future commentary is quite exciting. The underlining numbers, that most use to determine a companies value are either the same or unknown still. Still dont know sales, margins or conversion from waitlist. No new major pharma partnerships announced. There is also still uncertainty on costs and need for additional capital. Hence why I think the price is what it is. Saying that, I do agree with others, that OTC will be a catalyst. As will increasing our exposure to markets such as Europe and Asia. Early reviews are favourable which is also good. I also like the future commentary on their approach and rollout. If you look at Garmin and fitbit and how everyone suddenly wanted/used their products because of the insight into health and performance. Then it'll be exciting once/if word gets out what the Pulse can do. I think "the why and what" of what the Pulse does is understated. In speaking to my cardiologist, and hearing them explain all the insights blood pressure metrics and the like provide. I was floored. Lot of potential, still long way to go. Good to see old and new voices on the forum.
CDX Price at posting:
11.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)